
Pharmaids Pharmaceuticals Ltd Falls to 52-Week Low of Rs 25.46 as Sell-Off Deepens
2026-11-18 12:06:12For the fourth consecutive session, Pharmaids Pharmaceuticals Ltd has declined, culminating in a fresh 52-week low of Rs 25.46 on 18 Nov 2026. This marks an 11.26% drop over the past four days, underscoring persistent selling pressure despite a broader market that has been relatively resilient.
Read MorePharmaids Pharmaceuticals Ends Week Down 0.25% Amid Financial Struggles and Market Volatility
2026-11-14 15:02:42Key Events This Week Nov 09: Stock opens strong at Rs.30.00, gaining 5.01% Nov 11: Price retreats to Rs.29.17 amid broader market gains Nov 12: Negative financial trends reported; stock rebounds to Rs.29.84 Nov 13: Stock closes week lower at Rs.28.50, down 4.49% on the day Week Open Rs.28.57 <div clas...
Read More
Pharmaids Pharmaceuticals Ltd Reports Negative Financial Trend Amidst Margin Pressures
2026-11-12 11:00:22Pharmaids Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a marked deterioration in its recent quarterly financial performance. The company’s financial trend has shifted from flat to negative, reflecting significant contraction in revenue and profitability over the latest six-month period, raising concerns among investors and analysts alike.
Read More
Pharmaids Pharmaceuticals Ltd is Rated Strong Sell
2026-10-31 10:10:13Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 October 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Pharmaids Pharmaceuticals Ltd is Rated Strong Sell
2026-10-09 10:10:24Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 09 October 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trend, and technical outlook.
Read More
Pharmaids Pharmaceuticals Ltd is Rated Strong Sell
2026-09-28 10:10:23Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 28 September 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.
Read More
Pharmaids Pharmaceuticals Ltd is Rated Strong Sell
2026-09-17 10:10:27Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 17 September 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.
Read More
Pharmaids Pharmaceuticals Ltd is Rated Strong Sell
2026-09-02 10:10:26Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 02 September 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.
Read MoreClarification sought from Pharmaids Pharmaceuticals Ltd
20-Nov-2026 | Source : BSEThe Exchange has sought clarification from Pharmaids Pharmaceuticals Ltd on November 20 2026 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.
The reply is awaited.
Announcement under Regulation 30 (LODR)-Newspaper Publication
13-Nov-2026 | Source : BSENewspaper publication of Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30 2026
Board Meeting Outcome for Outcome Of The Board Meeting
11-Nov-2026 | Source : BSEoutcome of the Board Meeting held on Wednesday November 11 2026 i.e today to consider and approve unaudited financial results for the quarter and half year ended September 30 2026
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
